Ruthenium Compounds Differentially Inhibit Group IA and IIA Snake Venom Phospholipase A₂ Anticoagulant Activity.

Area of Science:

• Biochemistry
• Toxicology
• Pharmacology

Background:

• Snake venom phospholipase A2 (PLA2) enzymes from coral snakes and rattlesnakes cause significant neurotoxicity and anticoagulation.
• PLA2 enzymes bind to activated clotting factor X, leading to anticoagulation.
• Ruthenium (Ru)-containing compounds have shown potential in inactivating hemotoxic venoms in a solvent-dependent manner.

Purpose of the Study:

• To investigate the solvent-dependent inhibitory effects of ruthenium trichloride (RuCl3) on group IA and group IIA snake venom PLA2 activities.
• To assess the impact of RuCl3 on the anticoagulant properties of these PLA2 enzymes in human plasma using thrombelastography.

Main Methods:

• Utilized thrombelastography to measure the anticoagulant effects of snake venom PLA2 in human plasma.
• Tested the inhibitory activity of RuCl3 against group IA (Micrurus species) and group IIA (Crotalus scutulatus) PLA2 in two different solvents: 0.9% NaCl and phosphate-buffered saline (PBS).

Main Results:

• RuCl3 significantly reduced the anticoagulant effects of group IA PLA2 (from M. tener and M. fulvius) in 0.9% NaCl, but not in PBS.
• RuCl3 inhibited the anticoagulant activity of group IIA PLA2 (from C. scutulatus) in both 0.9% NaCl and PBS.
• Demonstrated a clear solvent-dependent inhibition of snake venom PLA2 by RuCl3.

Conclusions:

• The solvent in which RuCl3 is used influences its inhibitory effect on different groups of snake venom PLA2.
• The distinct inhibitory patterns suggest that RuCl3 may interact with unique structural features, possibly disulfide bridges, specific to group IA and IIA PLA2.
• Further in vivo studies are crucial to validate the therapeutic potential of Ru-based inhibitors against snake venom neurotoxicity.